Paul Hebeisen

In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci

Paul Hebeisen, Ingrid Heinze‐Krauss, Peter Angehrn et al. · Antimicrobial Agents and Chemotherapy · 2001 · 214 citations · Full text

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović et al. · Journal of Medicinal Chemistry · 2017 · 132 citations · Full text

Chemoprevention Strategy, Immunology, Clinical Candidate +19

Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders

Denise Rageot, Thomas Bohnacker, Anna Melone et al. · Journal of Medicinal Chemistry · 2018 · 83 citations · Full text

A New DNA Gyrase Inhibitor Subclass of the Cyclothialidine Family Based on a Bicyclic Dilactam−Lactone Scaffold. Synthesis and Antibacterial Properties

Peter Angehrn, Erwin Goetschi, Hans Gmuender et al. · Journal of Medicinal Chemistry · 2011 · 68 citations

Antimicrobial Chemotherapy, Bicyclic Dilactam−lactone Scaffold, Pharmaceutical Chemistry +17

New Antibacterial Agents Derived from the DNA Gyrase Inhibitor Cyclothialidine

Peter Angehrn, Stefan Buchmann, Christoph Funk et al. · Journal of Medicinal Chemistry · 2004 · 55 citations

Molecular Biology, Antimicrobial Chemotherapy, Chemical Biology +18